Beginning in July 2026, certain Medicare beneficiaries will have access to GLP-1 medications for a fixed monthly fee. This pilot program, known as the Medicare GLP-1 Bridge, is designed to run until the end of 2027. However, as the start date nears, questions about its operation remain.
Program Overview
The Centers for Medicare and Medicaid Services (CMS) announced that the program will operate from July 1, 2026, to December 31, 2027. It will allow eligible Medicare Part D participants to obtain GLP-1 medications for a $50 monthly copay. Though these medications aid diabetes, obesity, and heart conditions, the program mostly targets weight management.
This initiative aims to assist beneficiaries without a medically coverable indication for GLP-1s under Part D. Current federal law prevents Medicare from covering weight loss drugs specifically. While some, like the Obesity Care Advocacy Network, celebrate the program as a positive step against the obesity epidemic, others express concerns about its administration and costs.
Operational Details
CMS outlines that Medicare enrollees do not need extra paperwork to participate; they only need a prescription from their doctor. Healthcare providers must submit a prior authorization request and prescription for eligible medications like Wegovy, Zepbound, and Foundayo.
If a patient switches medications during the program, a new prior authorization is necessary. Once the prescription is sent to the pharmacy, it is directed to a central processor labeled as Bridge PCN by CMS.
Aurelia Chaudhury, leading CMS initiatives, emphasized that prior authorizations will not be processed ahead of time. Initial prescriptions missing an authorization will be rejected. Physicians attest that patients lack Type 2 diabetes, severe sleep apnea, or certain liver diseases. Claims process begins July 1, 2026.
Kelly Strachan from CMS states the program evaluates if uniform pricing for GLP-1s improves patient outcomes and reduces costs. The monthly fee does not contribute to deductible or out-of-pocket limits.
Eligibility Criteria
To participate, beneficiaries must be in a standalone prescription plan or a Medicare Advantage care plan. Special Needs Plans, employer or union group waiver plans, and Limited Income Transition participants qualify. Tricare coverage beneficiaries must also be in a suitable Part D plan.
The program applies to dual enrollees in Medicaid. Obesity specialist Dr. Catherine Varney highlights that patients at high risk of obesity-related diseases benefit most. Eligibility depends on body mass index (BMI) and specific health conditions like prediabetes or past heart issues.
Regulatory Concerns
The Bridge program deviates from normal Medicare operations, raising concerns about potential for fraud. The program opens Medicare to obesity prescriptions, some fearing it may lead to misuse. Healthcare counsel Christopher Frisina warns the program might attract new telehealth providers seeking Medicare reimbursement. Despite CMS’s precautions, risks remain.
CMS has not disclosed cost estimates or enrollment forecasts but confirms a $50 copay per drug supply. The program’s setup operates outside typical Medicare Part D structures for costs, not following standard procedures.